HCA Healthcare (HCA) EVP Michael Cuffe reports stock disposals
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe reported two transactions in HCA common stock on February 3, 2026. A transaction coded “S” showed the disposition of 1,500 shares at $498.0901 per share. A second transaction coded “G” reported 4,050 shares at $0 per share. After these transactions, he directly owned 25,952.9017 shares of HCA common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 1,500 shares ($747,135)
Net Sell
2 txns
Insider
Cuffe Michael S.
Role
EVP and Chief Clinical Officer
Sold
1,500 shs ($747K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,500 | $498.0901 | $747K |
| Gift | Common Stock | 4,050 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 30,002.902 shares (Direct)
Footnotes (1)
FAQ
What insider transaction did HCA EVP Michael S. Cuffe report for HCA Healthcare (HCA)?
Michael S. Cuffe reported two HCA Healthcare common stock transactions dated February 3, 2026. One transaction coded “S” disposed of 1,500 shares at $498.0901 per share, and another coded “G” covered 4,050 shares at $0 per share.
What does the transaction coded "G" involve in Michael S. Cuffe’s HCA Form 4?
The transaction coded “G” involves 4,050 HCA Healthcare common shares reported at a per-share price of $0. This entry appears as a disposition in the table and occurs on the same February 3, 2026 date as the 1,500-share “S” transaction.
What is Michael S. Cuffe’s role at HCA Healthcare in this Form 4 filing?
In this Form 4, Michael S. Cuffe is identified as an officer of HCA Healthcare. His title is Executive Vice President (EVP) and Chief Clinical Officer, and the form indicates the filing is made by one reporting person in that capacity.
Are Michael S. Cuffe’s HCA Healthcare holdings direct or indirect after the transactions?
The Form 4 shows Michael S. Cuffe’s HCA Healthcare holdings as directly owned after the transactions. The ownership form column lists “D” for direct ownership, with 25,952.9017 common shares beneficially owned following the reported February 3, 2026 activity.